Combined pharmaceutical composition for treating small cell lung cancer
The present invention relates to the field of biomedicine and relates to a combined pharmaceutical composition used for treating small cell lung cancer, the composition comprising an anti-PD-L1 antibody and anlotinib, and having good anti-small cell lung cancer activity.
1 . A method for treating small cell lung cancer, comprising administering to a subject an effective amount of an anti-PD-L1 antibody and anlotinib, wherein the anti-PD-L1 antibody comprises an amino acid sequence as follows: a heavy chain CDR1 region selected from the group consisting of SEQ ID NO: 1; a heavy chain CDR2 region selected from the group consisting of SEQ ID NO: 2; a heavy chain CDR3 region selected from the group consisting of SEQ ID NO: 3; a light chain CDR1 region selected from the group consisting of SEQ ID NO: 7; a light chain CDR2 region selected from the group consisting of SEQ ID NO: 8; and a light chain CDR3 region selected from the group consisting of SEQ ID NO: 9.
2 . The method according to claim 1 , wherein the method comprises administering a combination of the anti-PD-L1 antibody and anlotinib.
3 . The method according to claim 1 , wherein the anti-PD-L1 antibody and anlotinib are each in the form of a pharmaceutical composition that can be administered simultaneously, sequentially or at intervals.
4 . The method according to claim 1 , wherein the anti-PD-L1 antibody is administered once every week, every 2 weeks, every 3 weeks, or every 4 weeks.
5 . The method according to claim 4 , wherein the anti-PD-L1 antibody is administered at a dose of 600-2400 mg each time.
6 . The method according to claim 1 , wherein anlotinib is administered at a dose of 6 mg, 8 mg, 10 mg, or 12 mg once daily with a regimen of continuous 2-week treatment plus 1-week interruption.
7 . The method according to claim 3 , wherein the method comprises administering a pharmaceutical composition containing 600-2400 mg of the anti-PD-L1 antibody and a pharmaceutical composition containing anlotinib in a single dose of 6 mg, 8 mg, 10 mg and/or 12 mg.
8 . The method according to claim 1 , wherein the anti-PD-L1 antibody and anlotinib are packaged either separately or together.
9 . The method according to claim 1 , wherein the anti-PD-L1 antibody comprises an amino acid sequence as follows: a heavy chain variable region having at least 80% homology to an amino acid sequence set forth in SEQ ID NO: 13; and a light chain variable region having at least 80% homology to an amino acid sequence set forth in SEQ ID NO: 15.
10 . The method according to claim 1 , wherein the anti-PD-L1 antibody comprises an amino acid sequence as follows: a heavy chain amino acid sequence set forth in SEQ ID NO: 17; and a light chain amino acid sequence set forth in SEQ ID NO: 18.
11 . The method according to claim 1 , wherein a treatment cycle takes 21 days; 1200 mg of the anti-PD-L1 antibody is administered on the first day of each treatment cycle, and 6 mg, 8 mg, 10 mg or 12 mg of anlotinib is administered daily on days 1-14 of each treatment cycle.
12 . The method according to claim 1 , wherein the small cell lung cancer comprises limited-stage and extensive-stage small cell lung cancer;
the small cell lung cancer is recurrent and/or metastatic small cell lung cancer; or
the small cell lung cancer is advanced/metastatic small cell lung cancer.
13 . The method according to claim 9 , wherein the anti-PD-L1 antibody comprises: a heavy chain variable region having an amino acid sequence set forth in SEQ ID NO: 13, and a light chain variable region having an amino acid sequence set forth in SEQ ID NO: 15.